PCSK9 Inhibitor Evolocumab Continues to Lack Cost-Effectiveness
Findings for addition of evolocumab to standard tx in atherosclerotic cardiovascular disease
Findings for addition of evolocumab to standard tx in atherosclerotic cardiovascular disease
Despite more major bleeding events, rivaroxaban plus aspirin therapy had a greater cardiovascular benefit in patients with stable atherosclerotic vascular disease vs monotherapy.
Experts weigh in on how to improve racial and ethnic disparities in cardiovascular health.
Fourteen percent of study participants experienced incident athersclerotic cardiovascular disease events.
Hair whitening score, hypertension, and dyslipidemia were all independent predictors of atherosclerotic coronary artery disease.
Results of the FOURIER trial, presented at the 2017 ACC Scientific Sessions, raise questions about the efficacy of PCSK9 inhibitors as long-term therapy for patients with atherosclerotic CVD.
Two studies examined the positive outcomes of clear patient-clinician communication on management and treatment of heart disease.
A mutlimodal strategy combines 5 separate tests to significantly improve CVD and ASVCD risk assessment.
According to ACC/AHA Guidelines presented at ACC 2017, targeted imaging should be used to personalize statin recommendation programs.
Evolocumab reduced LDL-C levels by 59% and lowered the risk of CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization by 15%.